Project Grant R43GM122129

Federal Grant Award Summary Precision Quantomics, Inc. received a $570,888 Project Grant from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, awarded on August 15, 2025, with a completion date of August 14, 2026. This Phase I project aims to develop recombinant human enzyme panels representing genetic variants in drug-metabolizing enzymes present in the U.S. patient population. The deliverables include commercially viable kits and standardized recombinant protein...

Summary Piccolo Biosystems, Inc. received a $295,861 Phase I Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2026. In collaboration with the University of Washington, Piccolo will develop and validate an innovative picoliter-scale thin layer chromatography (PTLC) platform for measuring enzyme inhibition in...

Micropure Genomics Inc. received a $274,199 Project Grant award from the National Science Foundation to advance methods for rapid, end-to-end sample preparation for sequencing applications. Under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the company will develop an automated process relying on electro-hydrodynamic trapping to isolate genomic material like DNA or RNA from cells in a flow cartridge. The process aims to significantly reduce preparation time while...

Capienda Biotech, LLC received a $329,272 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective August 1, 2025 through July 31, 2026. The company is developing a high-throughput kinetic measurement instrument that significantly advances small-molecule drug discovery capabilities. Building on a prior National Science Foundation Small Business Innovation Research (SBIR) Phase I prototype that enabled 128 simultaneous assays, this award...

The federal Project Grant award of $283,805 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of a novel cell-free, high-throughput platform to expedite the engineering of enzymes for biocatalytic "BioClick" reactions. The project, undertaken by Invizyne Technologies, Inc., a small disadvantaged business in Monrovia, CA, focuses on establishing an efficient cell-free protein...

Omicscraft LLC received a $256,000 Project Grant from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041) to develop a cloud-based platform for analysis of untargeted metabolomics data. The platform will provide users an interactive modular interface to build customized pipelines for metabolomics data analysis from February 15, 2022 through July 31, 2022. Key deliverables include innovative computational methods for...

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...

Sinopia Biosciences Inc. received a $350,000 Project Grant awarded on August 1, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) administered by the National Institute of General Medical Sciences (NIGMS). This Phase I award supports the development of neural network models and integrated computational-experimental workflows to enable efficient metabolomic characterization of compound libraries for data-driven drug discovery (D4). The project builds on preliminary...

Federal Cooperative Agreement Summary The University of Pittsburgh received a $500,000 Cooperative Agreement from the Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103), awarded September 1, 2025, with completion scheduled for August 31, 2027. This award supports the development and qualification of the Liver Acinus Microphysiological Systems (LAMPS) platform as a drug development tool. The primary deliverable is the advancement of the...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...